Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Enrolling By Invitation
18-99 years
All
Phase
1
5 participants needed
1 Location
Brief description of study
ASTX295 is a synthetic small molecule that acts as an antagonist of Murine Double Minute 2 (MDM2; human homolog also known as HDM2). Study ASTX295-01 is a study with ASTX295 in subjects who are refractory or have relapsed after treatment with standard of care therapies, or for whom standard life-prolonging measures or approved therapies are not available.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: solid tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or over . with histologically or cytologically confirmed advanced solid tumors
Updated on
01 Aug 2024.
Study ID: 849700
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
